Erratum: Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.

Norihiko Suzuki,Fumio Nakagawa,Teiji Takechi

doi:10.3892/ol.2021.12772

Abstract

[This corrects the article DOI: 10.3892/ol.2017.6258.].

Highlights

To the publication of the above paper, after having re-examined their raw data the authors have realized that Fig. 6 and Table II contained miscalculations
The description of the CDDP dosing schedule was inaccurate: The CDDP dosing schedule on p. 640 of the Materials and methods section, right-hand column, “In vivo antitumor activity” subsection, should have been written as follows: “CDDP (7 mg/kg) was injected intravenously, once every 4 weeks, into the tail vein of mice for evaluating the effect on the gastric cancer MKN45 cell line”
The third sentence in the “Antitumor activity of TFTD in the human gastric MKN45 intraperitoneal xenograft model” subsection of the Results, towards the end of p. 642, should have read as follows: “TFTD exhibited a significant antitumor effect compared with S‐1 and CDDP in the MKN45 intraperitoneal xenograft model (P

Summary

Introduction

To the publication of the above paper, after having re-examined their raw data the authors have realized that Fig. 6 and Table II contained miscalculations. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer This figure and table appeared to show the results of one designated experiment, they were intended to represent the results of the integration of two independent experiments.

Results

Conclusion